Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel

Key Takeaways Tempus AI integrates Median's FDA-cleared eyonis LCS into its Pixel imaging platform.TEM aims to enhance lung cancer detection, risk scoring and radiology workflow efficiency.Shares of TEM rose 2.3% post-announcement despite a 33.7% six-month decline.Tempus AI, Inc. (TEM) recently announced a collaboration with Median Technologies to integrate Median’s proprietary eyonis LCS solution into the Tempus Pixel platform. The integration is expected to expand Pixel’s AI capabilities in lung cancer sc ...